

DAFTAR PUSTAKA

1. Caplan LR. Caplan's stroke: a clinical approach. 4th ed. Philadelphia: Saunders, 2009
2. Donnan GA, Dewey HM, Thrift AG, Sturm J. The Epidemiology of Stroke. In: Munsat TL, ed. Stroke: Selected Topics. New York: Demos Medical Publishing, 2007: 1-8.
3. Smith EE, Koroshetz WJ. Epidemiology of stroke. In: Furie KL, Kelly PJ, eds. Handbook of Stroke Prevention in Clinical Practice. New Jersey: Humana Press, 2004: 1-8.
4. Nys GMS, van Zandvoort MJE, Der Worp HB, De Haan EHF, De Kort PLM, Jansen BPW, Kappelle LJ. Early cognitive impairment predicts long-term depressive symptoms and quality of life after stroke. *J Neurol Sci* 2006;247(2):149-56
5. Zinn S, Dudley TK, Bosworth HB, Hoenig HM, Duncan PW, Horner RD. The Effect of Poststroke Cognitive Impairment on Rehabilitation Process and Functional Outcome. *Arch Phys Med Rehabil* 2004; 85:1084-9.
6. Desmond DW, Moroney JT, Sano M, Stern Y. Recovery of Cognitive Function After Stroke. *Stroke* 1996;27:1798-1803
7. Del Ser T, Barba R, Morin MM, Domingo J, Cemillan C, Pondal M, Vivancos J. Evolution of Cognitive Impairment After Stroke and Risk Factors for Delayed Progression. *Stroke* 2005;36:2670-5.
8. Serrano S, Domingo J, Garcia ER, Castro MD, Del Ser T. Frequency of Cognitive Impairment Without Dementia in Patients With Stroke: A Two-Year Follow-Up Study. *Stroke* 2007;38:105-10.
9. Zhao QL, Zhou Y, Wang YL, Dong KH, Wang YJ. A new diagnostic algorithm for vascular cognitive impairment: the proposed criteria and evaluation of its reliability and validity. *Chin Med J* 2010;123(3):311-9
10. Rasquin SMC, Verhey FRJ, van Oostenbrugge RJ, Lousberg R, Lodder J. Demographic and CT scan features related to cognitive impairment in the first year after stroke. *J Neurol Neurosurg Psychiatry* 2004;75:1562–1567.
11. Everson SA, Helkala EL, Kaplan GA, Salonen JT. Atherosclerosis and cognitive functioning. In: Waldstein SR, Elias MF, eds. Neuropsychology of Cardiovascular Disease. New Jersey: Lawrence Erlbaum Associates Inc, 2001:105-20
12. Wagle J, Farner L, Flekkøy K, Wyller TB, Sandvik L, Eiklid KL, et al. Association between ApoE epsilon4 and cognitive impairment after stroke. *Dement Geriatr Cogn Disord*. 2009;27(6):525-33.
13. Utermann G, Langenbeck U, Beisiegel U, Weber W. Genetics of the Apolipoprotein E System in Man. *Am J Hum Genet* 1980;32:339-47.
14. Nelson PT, Head E, Schmitt FA, Davis PR, Neltner JH, Jicha GA, et al. Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. *Acta Neuropathol* . 2011;121:571–87.
15. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. *Arterioscler Thromb Vasc Biol* 1988;8:1-21

16. Sing CF, Davignon J. Role of apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. *Am J Hum Genet*; 1985;37: 268-82
17. Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, Stern Y. Contribution of Vascular Risk Factors to the Progression in Alzheimer Disease. *Arch Neurol* 2009;66(3):343-8.
18. Leduc V, Belanger SJ, Poirier J. APOE and cholesterol homeostasis in Alzheimer's disease. *Trends in Molecular Medicine* 2010;16(10):469-75
19. Hauser PS, Narayanaswami V, Ryan RO. Apolipoprotein E: From lipid transport to neurobiology. *Progress in Lipid Research*. 2011;50:62-74.
20. Huang Y, Eckardstein A, Wu S, Assmann G. Effects of the Apolipoprotein E Polymorphism on Uptake and Transfer of Cell-derived Cholesterol in Plasma. *J Clin Invest*. 1995;96:2693-701.
21. Kawamata J, Tanaka S, Shimohama S, Ueda K, Kimura J. Apolipoprotein E polymorphism in Japanese patients with Alzheimer's disease or vascular dementia. *J Neurol Neurosurg Psych* 1994;57:1414-6.
22. Gofir A, Susilowati R, Zucha MA, Ar-Rochmah M, Zulyadaini E, Hidayati AZ. Apolipoprotein E polymorphism as a risk factor for Javanese with vascular dementia in Yogyakarta. *J Neuro Sci* 2009; 285(1): S267.
23. Ivan CS, Seshadri S, Beiser A, Au R, Kase CS, Kelly-Hayes M, Wolf PA. Dementia After Stroke: The Framingham Study. *Stroke*. 2004;35:1264-1269.
24. Knopman DS, Roberts RO, Geda YE, Boeve BF, Pankratz VS, Cha RH, Tangalos EG, et al. Association of Prior Stroke With Cognitive Function and Cognitive Impairment: A Population-Based Study. *Arch Neurol*. 2009;66(5):614-9.
25. Kuller LH, Shemanski L, Manolio T, Haan M, Fried L, Bryan N, Burke GL, et al. Relationship Between ApoE, MRI Findings, and Cognitive Function in the Cardiovascular Health Study. *Stroke* 1998;29:388-98.
26. Dik MG, Deeg DJH, Bouter LM, Corder EH, Kok A, Jonker C. Stroke and Apolipoprotein E ϵ 4 Are Independent Risk Factors for Cognitive Decline : A Population-Based Study. *Stroke* 2000;31:2431-6
27. Andhitara Y. Asosiasi Genotip Gen Apoe Dengan Profil Lipid Dan Ketebalan Tunika Intima-Media Arteri Karotis Interna Pada Pasien Pasca Stroke Iskemik [thesis]. Semarang (Indonesia): Universitas Diponegoro;2011
28. Bogousslavsky J, Liu M, Moncayo J, Norrving B, Tsiskaridze A, Yamaguchi T. Stroke. In: Aarli JA et al eds. *Neurological disorders: public health challenges*. Switzerland: World Health Organization, 2006:151.
29. Bustami M, ed. *Advanced neuro critical care support*. Jakarta: Indonesia Neurological Association 2010: 1
30. *Stroke in perspective: types of stroke*. Washington University 1999 [cited 2011 June 10]; Available from: http://www.strokecenter.org/education/ais_stroke_types/stroke_types.htm
31. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. A prospective study of acute cerebrovascular disease in the community-The Oxfordshire Community Stroke Project: 1981-1986. *J Neurol Neurosurg Psych* 1990;53:16-22.

32. Gottesman RF, Hillis AE. Predictors and assessment of cognitive dysfunction resulting from ischaemic stroke. *Lancet Neurol* 2010; 9: 895–905.
33. Nys GMS, Zandvoort MJE, De Kort PLM, Jansen BPW, Van Der Worp HB, Kappelle LJ, et al. Domain-specific cognitive recovery after first-ever stroke: a follow-up study of 111 cases. *J Int Neuropsychol Soc* 2005; 11: 795–806.
34. Lesniak M, Bak T, Czepiel W, Seniow J, Czlonkowska A. Frequency and prognostic value of cognitive disorders in stroke patients. *Dement Geriatr Cogn Disord* 2008; **26**: 356–63.
35. Saczynski JS, Sigurdsson S, Jonsdottir MK, Eiriksdottir G, Jonsson PV, Garcia ME, Kjartansson O, et al. Cerebral Infarcts and Cognitive Performance Importance of Location and Number of Infarcts. *Stroke*. 2009;40:677-682.
36. Pantoni L, Gorelick P. Advances in Vascular Cognitive Impairment 2010. *Stroke* 2011;42:291-3.
37. Sachdev PS, Chen X, Joscelyne A, Wen W, Altendorf A, Brodaty H. Hippocampal size and dementia in stroke patients: the Sydney Stroke Study. *J Neurol Sci* 2007; 260: 71–77.
38. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. *Lancet Neurol* 2009; 8: 1006–18.
39. Misbach J, Lamsudin R, Dikot Y, Lumempow SF, Anam. Pengenalan dini dan penatalaksanaan demensia vaskuler. Jakarta: Perdossi, 2006:1-4
40. Nadeau Y, Black SE. Mixed Dementia: The most common cause of dementia? *Canadian J Diag*. 2010.
41. Gorelick PB. Risk Factors for Vascular Dementia and Alzheimer Disease. *Stroke* 2004;35[*suppl I*]:2620-2622.
42. Astuti. Prognosis gangguan kognitif dan mild cognitive impairment pada usia lanjut. Dalam: Muhartomo H, Trianggoro B, eds. Update management of neurological disorders in elderly. Semarang: BP UNDIP, 2006: 68-75.
43. Rahmawati D. Diagnosis dan faktor risiko demensia vaskuler pada usia lanjut. Dalam: Muhartomo H, Trianggoro B, eds. Update management of neurological disorders in elderly. Semarang: BP UNDIP, 2006: 129-45.
44. Hartono B. Cognitive problems in elderly: the recent concept and approach. In: Soetedjo, Duarsa AB, eds. Cognitive problems in elderly. Semarang: BP UNDIP, 2002: 1-6.
45. Marshall RS, Lazar RM. Pumps, Aqueducts, and Drought Management: Vascular Physiology in Vascular Cognitive Impairment. *Stroke* 2011;42:221-6.
46. Kumar R, Looi JCL, and Raphael B. Type 2 diabetes mellitus, cognition and brain in aging: A brief review. *Indian J Psychiatry* 2009; 51(Suppl1): S35–8.
47. Di Legge S, Hachinski V. Vascular cognitive impairment (VCI): Progress towards knowledge and treatment. *Dement Neuropsychol* 2010;4(1):4-13.
48. Baune BT. The Puzzle of Predicting the Impact of Brain Infarcts on Cognitive Impairment in the Aging Brain. *Stroke* 2009;40:667-9.
49. Silbert LC, Howieson DB, Dodge H, Kaye JA. Cognitive impairment risk: white matter hyperintensity progression matters. *Neurology* 2009;73:120-5.

50. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MMB. Silent Brain Infarcts and the Risk of Dementia and Cognitive Decline. *N Engl J Med* 2003;348:1215-22.
51. Chabriat H, Godefroy O. Vascular dementia. In: Godefroy O, Bogousslavsky J, eds. *The Behavioral and Cognitive Neurology of Stroke*. Cambridge: Cambridge University Press, 2007: 596-8.
52. Jiwa NS, Garrard P, Hainsworth H. Experimental models of vascular dementia and vascular cognitive impairment: a systematic review. *J Neurochem* 2010;115: 822.
53. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: A HuGE review. *Am J Epidemiol* 2002;155:487-95.
54. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. *Science*; 1988;240: 622-30.
55. Venkatramana P, Reddy PC, Ferrell RE. Apolipoprotein E Polymorphism Among the Indian Populations and its Comparison with Other Asian Populations. *IJHG* 2001;1(2): 123-8.
56. Botham KM, Mayes PA. Lipid Transport & Storage. In : Murray RK, Bender DA, Botham KM, Kennelly PJ, Rodwell VW, Weil PA, eds. *Harper's Illustrated Biochemistry*. 28th Ed. New York: McGraw-Hill Co, 2009: 212-23
57. Hsiung GYR, Sadovnick D, Feldman H. Apolipoprotein E ϵ 4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. *CMAJ* 2004;171(8):863-7
58. Hooijmans CR, Kiliaan AJ. Fatty acids, lipid metabolism and Alzheimer pathology. *Eur J Pharm* 2008;585:176-96.
59. Bartzokis G, Lu PH, Geschwind DH, Tingus K, Huang D, Mendez MF, et al. Apolipoprotein E Affects Both Myelin Breakdown and Cognition: Implications for Age-Related Trajectories of Decline Into Dementia. *Biol Psychiatry* 2007;62:1380-1387
60. Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L. The Role of APOE ϵ 4 in Modulating Effects of Other Risk Factors for Cognitive Decline in Elderly Persons. *JAMA* 1999;281(1):40-5.
61. Abboud S, Viiri LE, Lütjohann D, Goebeler S, Luoto T, Friedrichs S, et al. Associations of apolipoprotein E gene with ischemic stroke and intracranial atherosclerosis. *Eur J Hum Genet* 2008;16, 955-60
62. Saidi S, Slamia LB, Ammou SB, Mahjoub T, Almawi WY. Association of apolipoprotein E gene polymorphism with ischemic stroke involving large-vessel disease and its relation to serum lipid levels. *J Stroke Cerebrovasc Dis* 2007;16(4):160-6
63. Hofman A, Ott A, Breteler MMB, Bots ML, Slioter AJC, vanHarskamp F, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. *Lancet* 1997;349:151-4.
64. Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, Stern Y, et al. Stroke and the Risk of Alzheimer Disease. *Arch Neurol* 2003;60:1707-12.
65. Horsburgh K, McCarron MO, Whitea F, Nicollb JAR. The role of apolipoprotein E in Alzheimer's disease, acute brain injury and

- cerebrovascular disease: evidence of common mechanisms and utility of animal models. *Neurobiology of Aging* 2000;21:245–55.
66. Hiekkänen H. Apolipoprotein E and recovery from traumatic brain injury [dissertation]. Turku: University of Turku; 2009.
 67. Mathew A, Yoshida Y, Maekawa T, Kumar DS. Alzheimer's disease: Cholesterol a menace? *Brain Res. Bull.* 2011.
 68. Bjorkhem I, Meaney S. Brain cholesterol: Long secret life behind a barrier. *Thromb Vasc Biol* 2004;24:804-15
 69. Riddell DR, Zhou H, Atchison K, Warwick HK, Atkinson PJ, Jefferson J, et al. Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels.
 70. Huang Y, Eckardstein A, Wu S, Assmann G. Effects of the Apolipoprotein E Polymorphism on Uptake and Transfer of Cell-derived Cholesterol in Plasma. *J Clin Invest.* 1995;96:2693-701.
 71. Gladstone. Alzheimer's disease and Apolipoprotein E.
 72. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucl Acids Res*; 1988; 16: 1215
 73. Wilson RS, Schneider JA, Barnes LL, Beckett LA, Aggarwal NT, Cochran EJ, et al. The Apolipoprotein E ϵ 4 Allele and Decline in Different Cognitive Systems During a 6-Year Period. *Arch Neurol.* 2002;59:1154-60.
 74. Liu F, Pardo LM, Schuur M, Juan PS, Isaacs A, Slegers K. The apolipoprotein E gene and its age-specific effects on cognitive function. *Neurobiol Aging* 2010;31:1831–3.
 75. Laczó J, Vlcek K, Vyhnalek M, Matoska V, Buksakowska I, Magerova H, et al. Apoe E4 Affects Spatial Working Memory and Attention In Patients With Amnesic Mild Cognitive Impairment. P3-053
 76. O'Hara R, Sommer B, Way N, Kraemer HC, Taylor J, Murphy G. Slower speed-of-processing of cognitive tasks is associated with presence of the Jagust W. Mapping Brain β -Amyloid. *Curr Opin Neurol.* 2009; 22(4): 356–61.
 77. Tosun D, Schuffa N, Sacreya DT, Shawc LM, Trojanowskic JQ, Aisen P, et al. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. *Neurobiol of Aging* 2010;31:1340–54.
 78. Raja P, Greenwood PM. The Apolipoprotein E Gene, Attention, and Brain Function. *Neuropsychol* 2002;16(2):254-74.
 79. Ross AJ, Sachdev PS, Wen W, Brodaty H, Joscelyne A, Lorentz LM. Prediction of cognitive decline after stroke using proton magnetic resonance spectroscopy. *J Neurol Sci* 2006;251:62–9
 80. Tatemichi TK, Desmond DW, Stern Y, Paik M, Sano M, Bagiella E. Cognitive impairment after stroke: frequency, patterns, and relationship to functional abilities. *J Neurol Neurosurg Psychiatry* 1994;57:202-207.
 81. Desmond DW, Moroney JT, Sano M, Stern Y, Merino JG. Incidence of Dementia After Ischemic Stroke: Results of a Longitudinal Study. *Stroke* 2002;33:2254-62.
 82. Tham W, Auchus AP, Thong M, Goh ML, Chang HM, Wong MC. Progression of cognitive impairment after stroke: One year results from a

- longitudinal study of Singaporean stroke patients. *J Neurol Sci* 2002;203–204:49–52.
83. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: New evidence from the Systolic Hypertension in Europe (Syst-Eur) study. *Arch Intern Med* 2002; 162:2046-2052.
 84. Yaffe K, Blackwell T, Whitmer RA, Krueger K, Barrett CE. Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. *J Nutr Health Aging*. 2006;10(4):293-5.
 85. Knopman DS, Roberts RO, Geda YE, Boeve BF, Pankratz VS, Cha RH, et al. Association of Prior Stroke With Cognitive Function and Cognitive Impairment : A Population-Based Study. *Arch Neurol*. 2009;66(5):614-619
 86. Khedr EM, Hamed SA, El-Shereef HK, Shawky OA, Mohamed KA, Awad EM, et al. Cognitive impairment after cerebrovascular stroke: Relationship to vascular risk factors. *Neuropsych Dis Treat* 2009;5:103–116.
 87. MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the risk of dementia, Alzheimer disease and vascular cognitive impairment in the Canadian study of health and aging. *Dement Geriatr Cogn Disord* 2002;14:77-83
 88. Solomon A, Kareholt I, Ngandu T, Wolozin B, MacDonald SWS, Winblad B, et al. Serum total cholesterol, statins and cognition in non-demented elderly. *Neurobiology of Aging* 2009;30:1006–9.
 89. Venkatramana P, Reddy PC, Ferrell RE. Apolipoprotein E Polymorphism Among the Indian Populations and its Comparison with Other Asian Populations. *IJHG*. 2001;1(2):123-128.
 90. Wagle J, Farmer L, Flekkøy K, Wyller TB, Sandvik L, Eiklid KL, et al. Association between ApoE epsilon4 and cognitive impairment after stroke. *Dement Geriatr Cogn Disord*. 2009;27(6):525-33.
 91. Wang Q, Yan J, Chen X, Li J, Yang Y, Weng JP, et al. Statins: Multiple neuroprotective mechanisms in neurodegenerative diseases. *Exper Neuro* 2011;230:27–34.
 92. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J: Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. *Lancet Neurol* 2006; 5: 735–741
 93. Sachdev PS, Brodaty H, Valenzuela MJ, Lorentz L, Looi JCL, Wen W, et al. The neuropsychological profile of vascular cognitive impairment in stroke and TIA patients. *Neurology* 2004;62:912–9.
 94. Schillerstrom JE, HortonMS, Royall DR. The Impact of Medical Illness on Executive Function. *Psychosomatics* 2005; 46:508–16

95. Baudic S, Barba GD, Thibaudet MC, Smagghec A, Remyd P, Traykov L. Executive function deficits in early Alzheimer's disease and their relations with episodic memory. *Arch Clin Neuropsychol* 21 (2006) 15–21.
96. Sarkkinen E, Korhonen M, Erkkilä A, Ebeling T, Uusitupa M. Effect of apolipoprotein E polymorphism on serum lipid response to the separate modification of dietary fat and dietary cholesterol. *Am J Clin Nutr* 1998;68:1215–22.
97. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. *Proc Natl Acad Sci* 2006;103(15):5644–51